IMMULAB - A Phase II Trial of Immunotherapy With Pembrolizumab in Combination With Local Ablation for Patients With Early Stage Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms IMMULAB
- 04 Jun 2019 Status changed from not yet recruiting to recruiting.
- 28 Feb 2019 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.
- 28 Feb 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Mar 2021.